How athletes’ rights can be better protected when it comes to retroactive Therapeutic Use Exemptions
Abstract Therapeutic Use Exemptions (‘TUEs’) provide athletes a route to take prohibited substances for medically supported therapeutic reasons without violating anti-doping rules. They were instituted for the purpose of protecting an athlete’s right to medical care; however, the current retroactive...
Ausführliche Beschreibung
Autor*in: |
Greene, Paul [verfasserIn] |
---|
Format: |
E-Artikel |
---|---|
Sprache: |
Englisch |
Erschienen: |
2019 |
---|
Schlagwörter: |
International Standard for Therapeutic Use Exemptions |
---|
Anmerkung: |
© T.M.C. Asser Instituut 2019 |
---|
Übergeordnetes Werk: |
Enthalten in: The international sports law journal - Berlin : Springer, 2002, 19(2019), 1-2 vom: 12. Juli, Seite 29-37 |
---|---|
Übergeordnetes Werk: |
volume:19 ; year:2019 ; number:1-2 ; day:12 ; month:07 ; pages:29-37 |
Links: |
---|
DOI / URN: |
10.1007/s40318-019-00154-7 |
---|
Katalog-ID: |
SPR036949566 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | SPR036949566 | ||
003 | DE-627 | ||
005 | 20230328165955.0 | ||
007 | cr uuu---uuuuu | ||
008 | 201007s2019 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1007/s40318-019-00154-7 |2 doi | |
035 | |a (DE-627)SPR036949566 | ||
035 | |a (SPR)s40318-019-00154-7-e | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Greene, Paul |e verfasserin |4 aut | |
245 | 1 | 0 | |a How athletes’ rights can be better protected when it comes to retroactive Therapeutic Use Exemptions |
264 | 1 | |c 2019 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a Computermedien |b c |2 rdamedia | ||
338 | |a Online-Ressource |b cr |2 rdacarrier | ||
500 | |a © T.M.C. Asser Instituut 2019 | ||
520 | |a Abstract Therapeutic Use Exemptions (‘TUEs’) provide athletes a route to take prohibited substances for medically supported therapeutic reasons without violating anti-doping rules. They were instituted for the purpose of protecting an athlete’s right to medical care; however, the current retroactive TUE policy under the World Anti-Doping Program fails to uphold this right. In order to obtain a retroactive TUE, athletes are required to prove not only that they meet the criteria for obtaining a prospective TUE (i.e., their use of a prohibited substance or method is medically necessary and will not enhance their performance above a normal state of health) but also that their circumstances fall into one of four ‘exceptions’. The ‘fairness provision’—the last of the four exceptions—is the ‘catch-all’ provision that permits athletes to receive a retroactive TUE only if both the World Anti-Doping Agency (‘WADA’) and the relevant Anti-Doping Organization agree that fairness requires the grant of a retroactive TUE. Since its inception, this ‘fairness provision’ has been narrowly interpreted by TUE Committees, thus preventing athletes from avoiding anti-doping rule violations even in instances where they have met the test to obtain a prospective TUE. The Ultimate Fighting Championship’s (‘UFC’) TUE Policy, in contrast to WADA’s policy, more broadly permits athletes to obtain retroactive TUEs, in the end helping them avoid getting caught up in the anti-doping system. As the fourth edition of the WADA Code will be approved in the next year, we believe WADA stakeholders should consider a broader and more equitable use of the ‘fairness’ provision or adapt its policy to better protect all athletes’ right to medical care. | ||
650 | 4 | |a Therapeutic Use Exemptions |7 (dpeaa)DE-He213 | |
650 | 4 | |a World Anti-Doping Code |7 (dpeaa)DE-He213 | |
650 | 4 | |a International Standard for Therapeutic Use Exemptions |7 (dpeaa)DE-He213 | |
650 | 4 | |a Ultimate Fighting Championship |7 (dpeaa)DE-He213 | |
650 | 4 | |a Retroactive TUE |7 (dpeaa)DE-He213 | |
650 | 4 | |a Prospective TUE |7 (dpeaa)DE-He213 | |
650 | 4 | |a Fairness |7 (dpeaa)DE-He213 | |
700 | 1 | |a Kaiser, Matthew |0 (orcid)0000-0002-2234-917X |4 aut | |
773 | 0 | 8 | |i Enthalten in |t The international sports law journal |d Berlin : Springer, 2002 |g 19(2019), 1-2 vom: 12. Juli, Seite 29-37 |w (DE-627)74670285X |w (DE-600)2716249-7 |x 2213-5154 |7 nnns |
773 | 1 | 8 | |g volume:19 |g year:2019 |g number:1-2 |g day:12 |g month:07 |g pages:29-37 |
856 | 4 | 0 | |u https://dx.doi.org/10.1007/s40318-019-00154-7 |z lizenzpflichtig |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a SYSFLAG_A | ||
912 | |a GBV_SPRINGER | ||
912 | |a GBV_ILN_11 | ||
912 | |a GBV_ILN_20 | ||
912 | |a GBV_ILN_22 | ||
912 | |a GBV_ILN_23 | ||
912 | |a GBV_ILN_24 | ||
912 | |a GBV_ILN_31 | ||
912 | |a GBV_ILN_32 | ||
912 | |a GBV_ILN_39 | ||
912 | |a GBV_ILN_40 | ||
912 | |a GBV_ILN_60 | ||
912 | |a GBV_ILN_62 | ||
912 | |a GBV_ILN_63 | ||
912 | |a GBV_ILN_65 | ||
912 | |a GBV_ILN_69 | ||
912 | |a GBV_ILN_70 | ||
912 | |a GBV_ILN_73 | ||
912 | |a GBV_ILN_74 | ||
912 | |a GBV_ILN_90 | ||
912 | |a GBV_ILN_95 | ||
912 | |a GBV_ILN_100 | ||
912 | |a GBV_ILN_105 | ||
912 | |a GBV_ILN_110 | ||
912 | |a GBV_ILN_120 | ||
912 | |a GBV_ILN_138 | ||
912 | |a GBV_ILN_150 | ||
912 | |a GBV_ILN_151 | ||
912 | |a GBV_ILN_161 | ||
912 | |a GBV_ILN_170 | ||
912 | |a GBV_ILN_171 | ||
912 | |a GBV_ILN_184 | ||
912 | |a GBV_ILN_187 | ||
912 | |a GBV_ILN_213 | ||
912 | |a GBV_ILN_224 | ||
912 | |a GBV_ILN_230 | ||
912 | |a GBV_ILN_250 | ||
912 | |a GBV_ILN_281 | ||
912 | |a GBV_ILN_285 | ||
912 | |a GBV_ILN_293 | ||
912 | |a GBV_ILN_370 | ||
912 | |a GBV_ILN_602 | ||
912 | |a GBV_ILN_636 | ||
912 | |a GBV_ILN_702 | ||
912 | |a GBV_ILN_2001 | ||
912 | |a GBV_ILN_2003 | ||
912 | |a GBV_ILN_2004 | ||
912 | |a GBV_ILN_2005 | ||
912 | |a GBV_ILN_2006 | ||
912 | |a GBV_ILN_2007 | ||
912 | |a GBV_ILN_2008 | ||
912 | |a GBV_ILN_2009 | ||
912 | |a GBV_ILN_2010 | ||
912 | |a GBV_ILN_2011 | ||
912 | |a GBV_ILN_2014 | ||
912 | |a GBV_ILN_2015 | ||
912 | |a GBV_ILN_2020 | ||
912 | |a GBV_ILN_2021 | ||
912 | |a GBV_ILN_2025 | ||
912 | |a GBV_ILN_2026 | ||
912 | |a GBV_ILN_2027 | ||
912 | |a GBV_ILN_2031 | ||
912 | |a GBV_ILN_2034 | ||
912 | |a GBV_ILN_2037 | ||
912 | |a GBV_ILN_2038 | ||
912 | |a GBV_ILN_2039 | ||
912 | |a GBV_ILN_2044 | ||
912 | |a GBV_ILN_2048 | ||
912 | |a GBV_ILN_2049 | ||
912 | |a GBV_ILN_2050 | ||
912 | |a GBV_ILN_2055 | ||
912 | |a GBV_ILN_2057 | ||
912 | |a GBV_ILN_2059 | ||
912 | |a GBV_ILN_2061 | ||
912 | |a GBV_ILN_2064 | ||
912 | |a GBV_ILN_2065 | ||
912 | |a GBV_ILN_2068 | ||
912 | |a GBV_ILN_2070 | ||
912 | |a GBV_ILN_2086 | ||
912 | |a GBV_ILN_2088 | ||
912 | |a GBV_ILN_2093 | ||
912 | |a GBV_ILN_2106 | ||
912 | |a GBV_ILN_2107 | ||
912 | |a GBV_ILN_2108 | ||
912 | |a GBV_ILN_2110 | ||
912 | |a GBV_ILN_2111 | ||
912 | |a GBV_ILN_2112 | ||
912 | |a GBV_ILN_2113 | ||
912 | |a GBV_ILN_2116 | ||
912 | |a GBV_ILN_2118 | ||
912 | |a GBV_ILN_2119 | ||
912 | |a GBV_ILN_2122 | ||
912 | |a GBV_ILN_2129 | ||
912 | |a GBV_ILN_2143 | ||
912 | |a GBV_ILN_2144 | ||
912 | |a GBV_ILN_2147 | ||
912 | |a GBV_ILN_2148 | ||
912 | |a GBV_ILN_2152 | ||
912 | |a GBV_ILN_2153 | ||
912 | |a GBV_ILN_2188 | ||
912 | |a GBV_ILN_2190 | ||
912 | |a GBV_ILN_2232 | ||
912 | |a GBV_ILN_2336 | ||
912 | |a GBV_ILN_2446 | ||
912 | |a GBV_ILN_2470 | ||
912 | |a GBV_ILN_2472 | ||
912 | |a GBV_ILN_2507 | ||
912 | |a GBV_ILN_2522 | ||
912 | |a GBV_ILN_2548 | ||
912 | |a GBV_ILN_4035 | ||
912 | |a GBV_ILN_4037 | ||
912 | |a GBV_ILN_4046 | ||
912 | |a GBV_ILN_4112 | ||
912 | |a GBV_ILN_4125 | ||
912 | |a GBV_ILN_4242 | ||
912 | |a GBV_ILN_4246 | ||
912 | |a GBV_ILN_4249 | ||
912 | |a GBV_ILN_4251 | ||
912 | |a GBV_ILN_4305 | ||
912 | |a GBV_ILN_4306 | ||
912 | |a GBV_ILN_4307 | ||
912 | |a GBV_ILN_4313 | ||
912 | |a GBV_ILN_4322 | ||
912 | |a GBV_ILN_4323 | ||
912 | |a GBV_ILN_4324 | ||
912 | |a GBV_ILN_4325 | ||
912 | |a GBV_ILN_4326 | ||
912 | |a GBV_ILN_4333 | ||
912 | |a GBV_ILN_4334 | ||
912 | |a GBV_ILN_4335 | ||
912 | |a GBV_ILN_4336 | ||
912 | |a GBV_ILN_4338 | ||
912 | |a GBV_ILN_4393 | ||
912 | |a GBV_ILN_4700 | ||
951 | |a AR | ||
952 | |d 19 |j 2019 |e 1-2 |b 12 |c 07 |h 29-37 |
author_variant |
p g pg m k mk |
---|---|
matchkey_str |
article:22135154:2019----::oaheergtcneetrrtceweicmsoeratvt |
hierarchy_sort_str |
2019 |
publishDate |
2019 |
allfields |
10.1007/s40318-019-00154-7 doi (DE-627)SPR036949566 (SPR)s40318-019-00154-7-e DE-627 ger DE-627 rakwb eng Greene, Paul verfasserin aut How athletes’ rights can be better protected when it comes to retroactive Therapeutic Use Exemptions 2019 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © T.M.C. Asser Instituut 2019 Abstract Therapeutic Use Exemptions (‘TUEs’) provide athletes a route to take prohibited substances for medically supported therapeutic reasons without violating anti-doping rules. They were instituted for the purpose of protecting an athlete’s right to medical care; however, the current retroactive TUE policy under the World Anti-Doping Program fails to uphold this right. In order to obtain a retroactive TUE, athletes are required to prove not only that they meet the criteria for obtaining a prospective TUE (i.e., their use of a prohibited substance or method is medically necessary and will not enhance their performance above a normal state of health) but also that their circumstances fall into one of four ‘exceptions’. The ‘fairness provision’—the last of the four exceptions—is the ‘catch-all’ provision that permits athletes to receive a retroactive TUE only if both the World Anti-Doping Agency (‘WADA’) and the relevant Anti-Doping Organization agree that fairness requires the grant of a retroactive TUE. Since its inception, this ‘fairness provision’ has been narrowly interpreted by TUE Committees, thus preventing athletes from avoiding anti-doping rule violations even in instances where they have met the test to obtain a prospective TUE. The Ultimate Fighting Championship’s (‘UFC’) TUE Policy, in contrast to WADA’s policy, more broadly permits athletes to obtain retroactive TUEs, in the end helping them avoid getting caught up in the anti-doping system. As the fourth edition of the WADA Code will be approved in the next year, we believe WADA stakeholders should consider a broader and more equitable use of the ‘fairness’ provision or adapt its policy to better protect all athletes’ right to medical care. Therapeutic Use Exemptions (dpeaa)DE-He213 World Anti-Doping Code (dpeaa)DE-He213 International Standard for Therapeutic Use Exemptions (dpeaa)DE-He213 Ultimate Fighting Championship (dpeaa)DE-He213 Retroactive TUE (dpeaa)DE-He213 Prospective TUE (dpeaa)DE-He213 Fairness (dpeaa)DE-He213 Kaiser, Matthew (orcid)0000-0002-2234-917X aut Enthalten in The international sports law journal Berlin : Springer, 2002 19(2019), 1-2 vom: 12. Juli, Seite 29-37 (DE-627)74670285X (DE-600)2716249-7 2213-5154 nnns volume:19 year:2019 number:1-2 day:12 month:07 pages:29-37 https://dx.doi.org/10.1007/s40318-019-00154-7 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_32 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_90 GBV_ILN_95 GBV_ILN_100 GBV_ILN_105 GBV_ILN_110 GBV_ILN_120 GBV_ILN_138 GBV_ILN_150 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_171 GBV_ILN_184 GBV_ILN_187 GBV_ILN_213 GBV_ILN_224 GBV_ILN_230 GBV_ILN_250 GBV_ILN_281 GBV_ILN_285 GBV_ILN_293 GBV_ILN_370 GBV_ILN_602 GBV_ILN_636 GBV_ILN_702 GBV_ILN_2001 GBV_ILN_2003 GBV_ILN_2004 GBV_ILN_2005 GBV_ILN_2006 GBV_ILN_2007 GBV_ILN_2008 GBV_ILN_2009 GBV_ILN_2010 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2015 GBV_ILN_2020 GBV_ILN_2021 GBV_ILN_2025 GBV_ILN_2026 GBV_ILN_2027 GBV_ILN_2031 GBV_ILN_2034 GBV_ILN_2037 GBV_ILN_2038 GBV_ILN_2039 GBV_ILN_2044 GBV_ILN_2048 GBV_ILN_2049 GBV_ILN_2050 GBV_ILN_2055 GBV_ILN_2057 GBV_ILN_2059 GBV_ILN_2061 GBV_ILN_2064 GBV_ILN_2065 GBV_ILN_2068 GBV_ILN_2070 GBV_ILN_2086 GBV_ILN_2088 GBV_ILN_2093 GBV_ILN_2106 GBV_ILN_2107 GBV_ILN_2108 GBV_ILN_2110 GBV_ILN_2111 GBV_ILN_2112 GBV_ILN_2113 GBV_ILN_2116 GBV_ILN_2118 GBV_ILN_2119 GBV_ILN_2122 GBV_ILN_2129 GBV_ILN_2143 GBV_ILN_2144 GBV_ILN_2147 GBV_ILN_2148 GBV_ILN_2152 GBV_ILN_2153 GBV_ILN_2188 GBV_ILN_2190 GBV_ILN_2232 GBV_ILN_2336 GBV_ILN_2446 GBV_ILN_2470 GBV_ILN_2472 GBV_ILN_2507 GBV_ILN_2522 GBV_ILN_2548 GBV_ILN_4035 GBV_ILN_4037 GBV_ILN_4046 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4242 GBV_ILN_4246 GBV_ILN_4249 GBV_ILN_4251 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4326 GBV_ILN_4333 GBV_ILN_4334 GBV_ILN_4335 GBV_ILN_4336 GBV_ILN_4338 GBV_ILN_4393 GBV_ILN_4700 AR 19 2019 1-2 12 07 29-37 |
spelling |
10.1007/s40318-019-00154-7 doi (DE-627)SPR036949566 (SPR)s40318-019-00154-7-e DE-627 ger DE-627 rakwb eng Greene, Paul verfasserin aut How athletes’ rights can be better protected when it comes to retroactive Therapeutic Use Exemptions 2019 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © T.M.C. Asser Instituut 2019 Abstract Therapeutic Use Exemptions (‘TUEs’) provide athletes a route to take prohibited substances for medically supported therapeutic reasons without violating anti-doping rules. They were instituted for the purpose of protecting an athlete’s right to medical care; however, the current retroactive TUE policy under the World Anti-Doping Program fails to uphold this right. In order to obtain a retroactive TUE, athletes are required to prove not only that they meet the criteria for obtaining a prospective TUE (i.e., their use of a prohibited substance or method is medically necessary and will not enhance their performance above a normal state of health) but also that their circumstances fall into one of four ‘exceptions’. The ‘fairness provision’—the last of the four exceptions—is the ‘catch-all’ provision that permits athletes to receive a retroactive TUE only if both the World Anti-Doping Agency (‘WADA’) and the relevant Anti-Doping Organization agree that fairness requires the grant of a retroactive TUE. Since its inception, this ‘fairness provision’ has been narrowly interpreted by TUE Committees, thus preventing athletes from avoiding anti-doping rule violations even in instances where they have met the test to obtain a prospective TUE. The Ultimate Fighting Championship’s (‘UFC’) TUE Policy, in contrast to WADA’s policy, more broadly permits athletes to obtain retroactive TUEs, in the end helping them avoid getting caught up in the anti-doping system. As the fourth edition of the WADA Code will be approved in the next year, we believe WADA stakeholders should consider a broader and more equitable use of the ‘fairness’ provision or adapt its policy to better protect all athletes’ right to medical care. Therapeutic Use Exemptions (dpeaa)DE-He213 World Anti-Doping Code (dpeaa)DE-He213 International Standard for Therapeutic Use Exemptions (dpeaa)DE-He213 Ultimate Fighting Championship (dpeaa)DE-He213 Retroactive TUE (dpeaa)DE-He213 Prospective TUE (dpeaa)DE-He213 Fairness (dpeaa)DE-He213 Kaiser, Matthew (orcid)0000-0002-2234-917X aut Enthalten in The international sports law journal Berlin : Springer, 2002 19(2019), 1-2 vom: 12. Juli, Seite 29-37 (DE-627)74670285X (DE-600)2716249-7 2213-5154 nnns volume:19 year:2019 number:1-2 day:12 month:07 pages:29-37 https://dx.doi.org/10.1007/s40318-019-00154-7 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_32 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_90 GBV_ILN_95 GBV_ILN_100 GBV_ILN_105 GBV_ILN_110 GBV_ILN_120 GBV_ILN_138 GBV_ILN_150 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_171 GBV_ILN_184 GBV_ILN_187 GBV_ILN_213 GBV_ILN_224 GBV_ILN_230 GBV_ILN_250 GBV_ILN_281 GBV_ILN_285 GBV_ILN_293 GBV_ILN_370 GBV_ILN_602 GBV_ILN_636 GBV_ILN_702 GBV_ILN_2001 GBV_ILN_2003 GBV_ILN_2004 GBV_ILN_2005 GBV_ILN_2006 GBV_ILN_2007 GBV_ILN_2008 GBV_ILN_2009 GBV_ILN_2010 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2015 GBV_ILN_2020 GBV_ILN_2021 GBV_ILN_2025 GBV_ILN_2026 GBV_ILN_2027 GBV_ILN_2031 GBV_ILN_2034 GBV_ILN_2037 GBV_ILN_2038 GBV_ILN_2039 GBV_ILN_2044 GBV_ILN_2048 GBV_ILN_2049 GBV_ILN_2050 GBV_ILN_2055 GBV_ILN_2057 GBV_ILN_2059 GBV_ILN_2061 GBV_ILN_2064 GBV_ILN_2065 GBV_ILN_2068 GBV_ILN_2070 GBV_ILN_2086 GBV_ILN_2088 GBV_ILN_2093 GBV_ILN_2106 GBV_ILN_2107 GBV_ILN_2108 GBV_ILN_2110 GBV_ILN_2111 GBV_ILN_2112 GBV_ILN_2113 GBV_ILN_2116 GBV_ILN_2118 GBV_ILN_2119 GBV_ILN_2122 GBV_ILN_2129 GBV_ILN_2143 GBV_ILN_2144 GBV_ILN_2147 GBV_ILN_2148 GBV_ILN_2152 GBV_ILN_2153 GBV_ILN_2188 GBV_ILN_2190 GBV_ILN_2232 GBV_ILN_2336 GBV_ILN_2446 GBV_ILN_2470 GBV_ILN_2472 GBV_ILN_2507 GBV_ILN_2522 GBV_ILN_2548 GBV_ILN_4035 GBV_ILN_4037 GBV_ILN_4046 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4242 GBV_ILN_4246 GBV_ILN_4249 GBV_ILN_4251 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4326 GBV_ILN_4333 GBV_ILN_4334 GBV_ILN_4335 GBV_ILN_4336 GBV_ILN_4338 GBV_ILN_4393 GBV_ILN_4700 AR 19 2019 1-2 12 07 29-37 |
allfields_unstemmed |
10.1007/s40318-019-00154-7 doi (DE-627)SPR036949566 (SPR)s40318-019-00154-7-e DE-627 ger DE-627 rakwb eng Greene, Paul verfasserin aut How athletes’ rights can be better protected when it comes to retroactive Therapeutic Use Exemptions 2019 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © T.M.C. Asser Instituut 2019 Abstract Therapeutic Use Exemptions (‘TUEs’) provide athletes a route to take prohibited substances for medically supported therapeutic reasons without violating anti-doping rules. They were instituted for the purpose of protecting an athlete’s right to medical care; however, the current retroactive TUE policy under the World Anti-Doping Program fails to uphold this right. In order to obtain a retroactive TUE, athletes are required to prove not only that they meet the criteria for obtaining a prospective TUE (i.e., their use of a prohibited substance or method is medically necessary and will not enhance their performance above a normal state of health) but also that their circumstances fall into one of four ‘exceptions’. The ‘fairness provision’—the last of the four exceptions—is the ‘catch-all’ provision that permits athletes to receive a retroactive TUE only if both the World Anti-Doping Agency (‘WADA’) and the relevant Anti-Doping Organization agree that fairness requires the grant of a retroactive TUE. Since its inception, this ‘fairness provision’ has been narrowly interpreted by TUE Committees, thus preventing athletes from avoiding anti-doping rule violations even in instances where they have met the test to obtain a prospective TUE. The Ultimate Fighting Championship’s (‘UFC’) TUE Policy, in contrast to WADA’s policy, more broadly permits athletes to obtain retroactive TUEs, in the end helping them avoid getting caught up in the anti-doping system. As the fourth edition of the WADA Code will be approved in the next year, we believe WADA stakeholders should consider a broader and more equitable use of the ‘fairness’ provision or adapt its policy to better protect all athletes’ right to medical care. Therapeutic Use Exemptions (dpeaa)DE-He213 World Anti-Doping Code (dpeaa)DE-He213 International Standard for Therapeutic Use Exemptions (dpeaa)DE-He213 Ultimate Fighting Championship (dpeaa)DE-He213 Retroactive TUE (dpeaa)DE-He213 Prospective TUE (dpeaa)DE-He213 Fairness (dpeaa)DE-He213 Kaiser, Matthew (orcid)0000-0002-2234-917X aut Enthalten in The international sports law journal Berlin : Springer, 2002 19(2019), 1-2 vom: 12. Juli, Seite 29-37 (DE-627)74670285X (DE-600)2716249-7 2213-5154 nnns volume:19 year:2019 number:1-2 day:12 month:07 pages:29-37 https://dx.doi.org/10.1007/s40318-019-00154-7 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_32 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_90 GBV_ILN_95 GBV_ILN_100 GBV_ILN_105 GBV_ILN_110 GBV_ILN_120 GBV_ILN_138 GBV_ILN_150 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_171 GBV_ILN_184 GBV_ILN_187 GBV_ILN_213 GBV_ILN_224 GBV_ILN_230 GBV_ILN_250 GBV_ILN_281 GBV_ILN_285 GBV_ILN_293 GBV_ILN_370 GBV_ILN_602 GBV_ILN_636 GBV_ILN_702 GBV_ILN_2001 GBV_ILN_2003 GBV_ILN_2004 GBV_ILN_2005 GBV_ILN_2006 GBV_ILN_2007 GBV_ILN_2008 GBV_ILN_2009 GBV_ILN_2010 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2015 GBV_ILN_2020 GBV_ILN_2021 GBV_ILN_2025 GBV_ILN_2026 GBV_ILN_2027 GBV_ILN_2031 GBV_ILN_2034 GBV_ILN_2037 GBV_ILN_2038 GBV_ILN_2039 GBV_ILN_2044 GBV_ILN_2048 GBV_ILN_2049 GBV_ILN_2050 GBV_ILN_2055 GBV_ILN_2057 GBV_ILN_2059 GBV_ILN_2061 GBV_ILN_2064 GBV_ILN_2065 GBV_ILN_2068 GBV_ILN_2070 GBV_ILN_2086 GBV_ILN_2088 GBV_ILN_2093 GBV_ILN_2106 GBV_ILN_2107 GBV_ILN_2108 GBV_ILN_2110 GBV_ILN_2111 GBV_ILN_2112 GBV_ILN_2113 GBV_ILN_2116 GBV_ILN_2118 GBV_ILN_2119 GBV_ILN_2122 GBV_ILN_2129 GBV_ILN_2143 GBV_ILN_2144 GBV_ILN_2147 GBV_ILN_2148 GBV_ILN_2152 GBV_ILN_2153 GBV_ILN_2188 GBV_ILN_2190 GBV_ILN_2232 GBV_ILN_2336 GBV_ILN_2446 GBV_ILN_2470 GBV_ILN_2472 GBV_ILN_2507 GBV_ILN_2522 GBV_ILN_2548 GBV_ILN_4035 GBV_ILN_4037 GBV_ILN_4046 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4242 GBV_ILN_4246 GBV_ILN_4249 GBV_ILN_4251 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4326 GBV_ILN_4333 GBV_ILN_4334 GBV_ILN_4335 GBV_ILN_4336 GBV_ILN_4338 GBV_ILN_4393 GBV_ILN_4700 AR 19 2019 1-2 12 07 29-37 |
allfieldsGer |
10.1007/s40318-019-00154-7 doi (DE-627)SPR036949566 (SPR)s40318-019-00154-7-e DE-627 ger DE-627 rakwb eng Greene, Paul verfasserin aut How athletes’ rights can be better protected when it comes to retroactive Therapeutic Use Exemptions 2019 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © T.M.C. Asser Instituut 2019 Abstract Therapeutic Use Exemptions (‘TUEs’) provide athletes a route to take prohibited substances for medically supported therapeutic reasons without violating anti-doping rules. They were instituted for the purpose of protecting an athlete’s right to medical care; however, the current retroactive TUE policy under the World Anti-Doping Program fails to uphold this right. In order to obtain a retroactive TUE, athletes are required to prove not only that they meet the criteria for obtaining a prospective TUE (i.e., their use of a prohibited substance or method is medically necessary and will not enhance their performance above a normal state of health) but also that their circumstances fall into one of four ‘exceptions’. The ‘fairness provision’—the last of the four exceptions—is the ‘catch-all’ provision that permits athletes to receive a retroactive TUE only if both the World Anti-Doping Agency (‘WADA’) and the relevant Anti-Doping Organization agree that fairness requires the grant of a retroactive TUE. Since its inception, this ‘fairness provision’ has been narrowly interpreted by TUE Committees, thus preventing athletes from avoiding anti-doping rule violations even in instances where they have met the test to obtain a prospective TUE. The Ultimate Fighting Championship’s (‘UFC’) TUE Policy, in contrast to WADA’s policy, more broadly permits athletes to obtain retroactive TUEs, in the end helping them avoid getting caught up in the anti-doping system. As the fourth edition of the WADA Code will be approved in the next year, we believe WADA stakeholders should consider a broader and more equitable use of the ‘fairness’ provision or adapt its policy to better protect all athletes’ right to medical care. Therapeutic Use Exemptions (dpeaa)DE-He213 World Anti-Doping Code (dpeaa)DE-He213 International Standard for Therapeutic Use Exemptions (dpeaa)DE-He213 Ultimate Fighting Championship (dpeaa)DE-He213 Retroactive TUE (dpeaa)DE-He213 Prospective TUE (dpeaa)DE-He213 Fairness (dpeaa)DE-He213 Kaiser, Matthew (orcid)0000-0002-2234-917X aut Enthalten in The international sports law journal Berlin : Springer, 2002 19(2019), 1-2 vom: 12. Juli, Seite 29-37 (DE-627)74670285X (DE-600)2716249-7 2213-5154 nnns volume:19 year:2019 number:1-2 day:12 month:07 pages:29-37 https://dx.doi.org/10.1007/s40318-019-00154-7 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_32 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_90 GBV_ILN_95 GBV_ILN_100 GBV_ILN_105 GBV_ILN_110 GBV_ILN_120 GBV_ILN_138 GBV_ILN_150 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_171 GBV_ILN_184 GBV_ILN_187 GBV_ILN_213 GBV_ILN_224 GBV_ILN_230 GBV_ILN_250 GBV_ILN_281 GBV_ILN_285 GBV_ILN_293 GBV_ILN_370 GBV_ILN_602 GBV_ILN_636 GBV_ILN_702 GBV_ILN_2001 GBV_ILN_2003 GBV_ILN_2004 GBV_ILN_2005 GBV_ILN_2006 GBV_ILN_2007 GBV_ILN_2008 GBV_ILN_2009 GBV_ILN_2010 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2015 GBV_ILN_2020 GBV_ILN_2021 GBV_ILN_2025 GBV_ILN_2026 GBV_ILN_2027 GBV_ILN_2031 GBV_ILN_2034 GBV_ILN_2037 GBV_ILN_2038 GBV_ILN_2039 GBV_ILN_2044 GBV_ILN_2048 GBV_ILN_2049 GBV_ILN_2050 GBV_ILN_2055 GBV_ILN_2057 GBV_ILN_2059 GBV_ILN_2061 GBV_ILN_2064 GBV_ILN_2065 GBV_ILN_2068 GBV_ILN_2070 GBV_ILN_2086 GBV_ILN_2088 GBV_ILN_2093 GBV_ILN_2106 GBV_ILN_2107 GBV_ILN_2108 GBV_ILN_2110 GBV_ILN_2111 GBV_ILN_2112 GBV_ILN_2113 GBV_ILN_2116 GBV_ILN_2118 GBV_ILN_2119 GBV_ILN_2122 GBV_ILN_2129 GBV_ILN_2143 GBV_ILN_2144 GBV_ILN_2147 GBV_ILN_2148 GBV_ILN_2152 GBV_ILN_2153 GBV_ILN_2188 GBV_ILN_2190 GBV_ILN_2232 GBV_ILN_2336 GBV_ILN_2446 GBV_ILN_2470 GBV_ILN_2472 GBV_ILN_2507 GBV_ILN_2522 GBV_ILN_2548 GBV_ILN_4035 GBV_ILN_4037 GBV_ILN_4046 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4242 GBV_ILN_4246 GBV_ILN_4249 GBV_ILN_4251 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4326 GBV_ILN_4333 GBV_ILN_4334 GBV_ILN_4335 GBV_ILN_4336 GBV_ILN_4338 GBV_ILN_4393 GBV_ILN_4700 AR 19 2019 1-2 12 07 29-37 |
allfieldsSound |
10.1007/s40318-019-00154-7 doi (DE-627)SPR036949566 (SPR)s40318-019-00154-7-e DE-627 ger DE-627 rakwb eng Greene, Paul verfasserin aut How athletes’ rights can be better protected when it comes to retroactive Therapeutic Use Exemptions 2019 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © T.M.C. Asser Instituut 2019 Abstract Therapeutic Use Exemptions (‘TUEs’) provide athletes a route to take prohibited substances for medically supported therapeutic reasons without violating anti-doping rules. They were instituted for the purpose of protecting an athlete’s right to medical care; however, the current retroactive TUE policy under the World Anti-Doping Program fails to uphold this right. In order to obtain a retroactive TUE, athletes are required to prove not only that they meet the criteria for obtaining a prospective TUE (i.e., their use of a prohibited substance or method is medically necessary and will not enhance their performance above a normal state of health) but also that their circumstances fall into one of four ‘exceptions’. The ‘fairness provision’—the last of the four exceptions—is the ‘catch-all’ provision that permits athletes to receive a retroactive TUE only if both the World Anti-Doping Agency (‘WADA’) and the relevant Anti-Doping Organization agree that fairness requires the grant of a retroactive TUE. Since its inception, this ‘fairness provision’ has been narrowly interpreted by TUE Committees, thus preventing athletes from avoiding anti-doping rule violations even in instances where they have met the test to obtain a prospective TUE. The Ultimate Fighting Championship’s (‘UFC’) TUE Policy, in contrast to WADA’s policy, more broadly permits athletes to obtain retroactive TUEs, in the end helping them avoid getting caught up in the anti-doping system. As the fourth edition of the WADA Code will be approved in the next year, we believe WADA stakeholders should consider a broader and more equitable use of the ‘fairness’ provision or adapt its policy to better protect all athletes’ right to medical care. Therapeutic Use Exemptions (dpeaa)DE-He213 World Anti-Doping Code (dpeaa)DE-He213 International Standard for Therapeutic Use Exemptions (dpeaa)DE-He213 Ultimate Fighting Championship (dpeaa)DE-He213 Retroactive TUE (dpeaa)DE-He213 Prospective TUE (dpeaa)DE-He213 Fairness (dpeaa)DE-He213 Kaiser, Matthew (orcid)0000-0002-2234-917X aut Enthalten in The international sports law journal Berlin : Springer, 2002 19(2019), 1-2 vom: 12. Juli, Seite 29-37 (DE-627)74670285X (DE-600)2716249-7 2213-5154 nnns volume:19 year:2019 number:1-2 day:12 month:07 pages:29-37 https://dx.doi.org/10.1007/s40318-019-00154-7 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_32 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_90 GBV_ILN_95 GBV_ILN_100 GBV_ILN_105 GBV_ILN_110 GBV_ILN_120 GBV_ILN_138 GBV_ILN_150 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_171 GBV_ILN_184 GBV_ILN_187 GBV_ILN_213 GBV_ILN_224 GBV_ILN_230 GBV_ILN_250 GBV_ILN_281 GBV_ILN_285 GBV_ILN_293 GBV_ILN_370 GBV_ILN_602 GBV_ILN_636 GBV_ILN_702 GBV_ILN_2001 GBV_ILN_2003 GBV_ILN_2004 GBV_ILN_2005 GBV_ILN_2006 GBV_ILN_2007 GBV_ILN_2008 GBV_ILN_2009 GBV_ILN_2010 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2015 GBV_ILN_2020 GBV_ILN_2021 GBV_ILN_2025 GBV_ILN_2026 GBV_ILN_2027 GBV_ILN_2031 GBV_ILN_2034 GBV_ILN_2037 GBV_ILN_2038 GBV_ILN_2039 GBV_ILN_2044 GBV_ILN_2048 GBV_ILN_2049 GBV_ILN_2050 GBV_ILN_2055 GBV_ILN_2057 GBV_ILN_2059 GBV_ILN_2061 GBV_ILN_2064 GBV_ILN_2065 GBV_ILN_2068 GBV_ILN_2070 GBV_ILN_2086 GBV_ILN_2088 GBV_ILN_2093 GBV_ILN_2106 GBV_ILN_2107 GBV_ILN_2108 GBV_ILN_2110 GBV_ILN_2111 GBV_ILN_2112 GBV_ILN_2113 GBV_ILN_2116 GBV_ILN_2118 GBV_ILN_2119 GBV_ILN_2122 GBV_ILN_2129 GBV_ILN_2143 GBV_ILN_2144 GBV_ILN_2147 GBV_ILN_2148 GBV_ILN_2152 GBV_ILN_2153 GBV_ILN_2188 GBV_ILN_2190 GBV_ILN_2232 GBV_ILN_2336 GBV_ILN_2446 GBV_ILN_2470 GBV_ILN_2472 GBV_ILN_2507 GBV_ILN_2522 GBV_ILN_2548 GBV_ILN_4035 GBV_ILN_4037 GBV_ILN_4046 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4242 GBV_ILN_4246 GBV_ILN_4249 GBV_ILN_4251 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4326 GBV_ILN_4333 GBV_ILN_4334 GBV_ILN_4335 GBV_ILN_4336 GBV_ILN_4338 GBV_ILN_4393 GBV_ILN_4700 AR 19 2019 1-2 12 07 29-37 |
language |
English |
source |
Enthalten in The international sports law journal 19(2019), 1-2 vom: 12. Juli, Seite 29-37 volume:19 year:2019 number:1-2 day:12 month:07 pages:29-37 |
sourceStr |
Enthalten in The international sports law journal 19(2019), 1-2 vom: 12. Juli, Seite 29-37 volume:19 year:2019 number:1-2 day:12 month:07 pages:29-37 |
format_phy_str_mv |
Article |
institution |
findex.gbv.de |
topic_facet |
Therapeutic Use Exemptions World Anti-Doping Code International Standard for Therapeutic Use Exemptions Ultimate Fighting Championship Retroactive TUE Prospective TUE Fairness |
isfreeaccess_bool |
false |
container_title |
The international sports law journal |
authorswithroles_txt_mv |
Greene, Paul @@aut@@ Kaiser, Matthew @@aut@@ |
publishDateDaySort_date |
2019-07-12T00:00:00Z |
hierarchy_top_id |
74670285X |
id |
SPR036949566 |
language_de |
englisch |
fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">SPR036949566</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230328165955.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">201007s2019 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1007/s40318-019-00154-7</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)SPR036949566</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(SPR)s40318-019-00154-7-e</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Greene, Paul</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">How athletes’ rights can be better protected when it comes to retroactive Therapeutic Use Exemptions</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2019</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">© T.M.C. Asser Instituut 2019</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Abstract Therapeutic Use Exemptions (‘TUEs’) provide athletes a route to take prohibited substances for medically supported therapeutic reasons without violating anti-doping rules. They were instituted for the purpose of protecting an athlete’s right to medical care; however, the current retroactive TUE policy under the World Anti-Doping Program fails to uphold this right. In order to obtain a retroactive TUE, athletes are required to prove not only that they meet the criteria for obtaining a prospective TUE (i.e., their use of a prohibited substance or method is medically necessary and will not enhance their performance above a normal state of health) but also that their circumstances fall into one of four ‘exceptions’. The ‘fairness provision’—the last of the four exceptions—is the ‘catch-all’ provision that permits athletes to receive a retroactive TUE only if both the World Anti-Doping Agency (‘WADA’) and the relevant Anti-Doping Organization agree that fairness requires the grant of a retroactive TUE. Since its inception, this ‘fairness provision’ has been narrowly interpreted by TUE Committees, thus preventing athletes from avoiding anti-doping rule violations even in instances where they have met the test to obtain a prospective TUE. The Ultimate Fighting Championship’s (‘UFC’) TUE Policy, in contrast to WADA’s policy, more broadly permits athletes to obtain retroactive TUEs, in the end helping them avoid getting caught up in the anti-doping system. As the fourth edition of the WADA Code will be approved in the next year, we believe WADA stakeholders should consider a broader and more equitable use of the ‘fairness’ provision or adapt its policy to better protect all athletes’ right to medical care.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Therapeutic Use Exemptions</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">World Anti-Doping Code</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">International Standard for Therapeutic Use Exemptions</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Ultimate Fighting Championship</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Retroactive TUE</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Prospective TUE</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Fairness</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Kaiser, Matthew</subfield><subfield code="0">(orcid)0000-0002-2234-917X</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="t">The international sports law journal</subfield><subfield code="d">Berlin : Springer, 2002</subfield><subfield code="g">19(2019), 1-2 vom: 12. Juli, Seite 29-37</subfield><subfield code="w">(DE-627)74670285X</subfield><subfield code="w">(DE-600)2716249-7</subfield><subfield code="x">2213-5154</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:19</subfield><subfield code="g">year:2019</subfield><subfield code="g">number:1-2</subfield><subfield code="g">day:12</subfield><subfield code="g">month:07</subfield><subfield code="g">pages:29-37</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://dx.doi.org/10.1007/s40318-019-00154-7</subfield><subfield code="z">lizenzpflichtig</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_SPRINGER</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_11</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_31</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_32</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_70</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_90</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_100</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_120</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_138</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_150</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_171</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_184</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_187</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_224</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_250</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_281</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_370</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_636</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_702</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2001</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2003</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2004</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2005</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2006</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2007</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2008</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2009</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2010</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2011</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2015</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2020</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2021</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2025</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2026</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2027</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2031</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2034</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2038</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2039</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2044</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2048</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2049</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2050</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2055</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2057</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2059</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2061</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2064</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2065</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2068</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2070</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2086</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2088</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2093</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2106</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2107</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2108</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2111</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2113</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2116</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2118</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2119</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2122</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2129</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2143</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2144</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2147</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2148</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2152</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2153</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2188</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2190</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2232</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2336</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2446</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2470</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2472</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2507</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2522</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2548</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4035</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4046</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4242</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4246</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4251</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4326</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4333</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4334</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4335</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4336</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4393</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">19</subfield><subfield code="j">2019</subfield><subfield code="e">1-2</subfield><subfield code="b">12</subfield><subfield code="c">07</subfield><subfield code="h">29-37</subfield></datafield></record></collection>
|
author |
Greene, Paul |
spellingShingle |
Greene, Paul misc Therapeutic Use Exemptions misc World Anti-Doping Code misc International Standard for Therapeutic Use Exemptions misc Ultimate Fighting Championship misc Retroactive TUE misc Prospective TUE misc Fairness How athletes’ rights can be better protected when it comes to retroactive Therapeutic Use Exemptions |
authorStr |
Greene, Paul |
ppnlink_with_tag_str_mv |
@@773@@(DE-627)74670285X |
format |
electronic Article |
delete_txt_mv |
keep |
author_role |
aut aut |
collection |
springer |
remote_str |
true |
illustrated |
Not Illustrated |
issn |
2213-5154 |
topic_title |
How athletes’ rights can be better protected when it comes to retroactive Therapeutic Use Exemptions Therapeutic Use Exemptions (dpeaa)DE-He213 World Anti-Doping Code (dpeaa)DE-He213 International Standard for Therapeutic Use Exemptions (dpeaa)DE-He213 Ultimate Fighting Championship (dpeaa)DE-He213 Retroactive TUE (dpeaa)DE-He213 Prospective TUE (dpeaa)DE-He213 Fairness (dpeaa)DE-He213 |
topic |
misc Therapeutic Use Exemptions misc World Anti-Doping Code misc International Standard for Therapeutic Use Exemptions misc Ultimate Fighting Championship misc Retroactive TUE misc Prospective TUE misc Fairness |
topic_unstemmed |
misc Therapeutic Use Exemptions misc World Anti-Doping Code misc International Standard for Therapeutic Use Exemptions misc Ultimate Fighting Championship misc Retroactive TUE misc Prospective TUE misc Fairness |
topic_browse |
misc Therapeutic Use Exemptions misc World Anti-Doping Code misc International Standard for Therapeutic Use Exemptions misc Ultimate Fighting Championship misc Retroactive TUE misc Prospective TUE misc Fairness |
format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
format_main_str_mv |
Text Zeitschrift/Artikel |
carriertype_str_mv |
cr |
hierarchy_parent_title |
The international sports law journal |
hierarchy_parent_id |
74670285X |
hierarchy_top_title |
The international sports law journal |
isfreeaccess_txt |
false |
familylinks_str_mv |
(DE-627)74670285X (DE-600)2716249-7 |
title |
How athletes’ rights can be better protected when it comes to retroactive Therapeutic Use Exemptions |
ctrlnum |
(DE-627)SPR036949566 (SPR)s40318-019-00154-7-e |
title_full |
How athletes’ rights can be better protected when it comes to retroactive Therapeutic Use Exemptions |
author_sort |
Greene, Paul |
journal |
The international sports law journal |
journalStr |
The international sports law journal |
lang_code |
eng |
isOA_bool |
false |
recordtype |
marc |
publishDateSort |
2019 |
contenttype_str_mv |
txt |
container_start_page |
29 |
author_browse |
Greene, Paul Kaiser, Matthew |
container_volume |
19 |
format_se |
Elektronische Aufsätze |
author-letter |
Greene, Paul |
doi_str_mv |
10.1007/s40318-019-00154-7 |
normlink |
(ORCID)0000-0002-2234-917X |
normlink_prefix_str_mv |
(orcid)0000-0002-2234-917X |
title_sort |
how athletes’ rights can be better protected when it comes to retroactive therapeutic use exemptions |
title_auth |
How athletes’ rights can be better protected when it comes to retroactive Therapeutic Use Exemptions |
abstract |
Abstract Therapeutic Use Exemptions (‘TUEs’) provide athletes a route to take prohibited substances for medically supported therapeutic reasons without violating anti-doping rules. They were instituted for the purpose of protecting an athlete’s right to medical care; however, the current retroactive TUE policy under the World Anti-Doping Program fails to uphold this right. In order to obtain a retroactive TUE, athletes are required to prove not only that they meet the criteria for obtaining a prospective TUE (i.e., their use of a prohibited substance or method is medically necessary and will not enhance their performance above a normal state of health) but also that their circumstances fall into one of four ‘exceptions’. The ‘fairness provision’—the last of the four exceptions—is the ‘catch-all’ provision that permits athletes to receive a retroactive TUE only if both the World Anti-Doping Agency (‘WADA’) and the relevant Anti-Doping Organization agree that fairness requires the grant of a retroactive TUE. Since its inception, this ‘fairness provision’ has been narrowly interpreted by TUE Committees, thus preventing athletes from avoiding anti-doping rule violations even in instances where they have met the test to obtain a prospective TUE. The Ultimate Fighting Championship’s (‘UFC’) TUE Policy, in contrast to WADA’s policy, more broadly permits athletes to obtain retroactive TUEs, in the end helping them avoid getting caught up in the anti-doping system. As the fourth edition of the WADA Code will be approved in the next year, we believe WADA stakeholders should consider a broader and more equitable use of the ‘fairness’ provision or adapt its policy to better protect all athletes’ right to medical care. © T.M.C. Asser Instituut 2019 |
abstractGer |
Abstract Therapeutic Use Exemptions (‘TUEs’) provide athletes a route to take prohibited substances for medically supported therapeutic reasons without violating anti-doping rules. They were instituted for the purpose of protecting an athlete’s right to medical care; however, the current retroactive TUE policy under the World Anti-Doping Program fails to uphold this right. In order to obtain a retroactive TUE, athletes are required to prove not only that they meet the criteria for obtaining a prospective TUE (i.e., their use of a prohibited substance or method is medically necessary and will not enhance their performance above a normal state of health) but also that their circumstances fall into one of four ‘exceptions’. The ‘fairness provision’—the last of the four exceptions—is the ‘catch-all’ provision that permits athletes to receive a retroactive TUE only if both the World Anti-Doping Agency (‘WADA’) and the relevant Anti-Doping Organization agree that fairness requires the grant of a retroactive TUE. Since its inception, this ‘fairness provision’ has been narrowly interpreted by TUE Committees, thus preventing athletes from avoiding anti-doping rule violations even in instances where they have met the test to obtain a prospective TUE. The Ultimate Fighting Championship’s (‘UFC’) TUE Policy, in contrast to WADA’s policy, more broadly permits athletes to obtain retroactive TUEs, in the end helping them avoid getting caught up in the anti-doping system. As the fourth edition of the WADA Code will be approved in the next year, we believe WADA stakeholders should consider a broader and more equitable use of the ‘fairness’ provision or adapt its policy to better protect all athletes’ right to medical care. © T.M.C. Asser Instituut 2019 |
abstract_unstemmed |
Abstract Therapeutic Use Exemptions (‘TUEs’) provide athletes a route to take prohibited substances for medically supported therapeutic reasons without violating anti-doping rules. They were instituted for the purpose of protecting an athlete’s right to medical care; however, the current retroactive TUE policy under the World Anti-Doping Program fails to uphold this right. In order to obtain a retroactive TUE, athletes are required to prove not only that they meet the criteria for obtaining a prospective TUE (i.e., their use of a prohibited substance or method is medically necessary and will not enhance their performance above a normal state of health) but also that their circumstances fall into one of four ‘exceptions’. The ‘fairness provision’—the last of the four exceptions—is the ‘catch-all’ provision that permits athletes to receive a retroactive TUE only if both the World Anti-Doping Agency (‘WADA’) and the relevant Anti-Doping Organization agree that fairness requires the grant of a retroactive TUE. Since its inception, this ‘fairness provision’ has been narrowly interpreted by TUE Committees, thus preventing athletes from avoiding anti-doping rule violations even in instances where they have met the test to obtain a prospective TUE. The Ultimate Fighting Championship’s (‘UFC’) TUE Policy, in contrast to WADA’s policy, more broadly permits athletes to obtain retroactive TUEs, in the end helping them avoid getting caught up in the anti-doping system. As the fourth edition of the WADA Code will be approved in the next year, we believe WADA stakeholders should consider a broader and more equitable use of the ‘fairness’ provision or adapt its policy to better protect all athletes’ right to medical care. © T.M.C. Asser Instituut 2019 |
collection_details |
GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_32 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_90 GBV_ILN_95 GBV_ILN_100 GBV_ILN_105 GBV_ILN_110 GBV_ILN_120 GBV_ILN_138 GBV_ILN_150 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_171 GBV_ILN_184 GBV_ILN_187 GBV_ILN_213 GBV_ILN_224 GBV_ILN_230 GBV_ILN_250 GBV_ILN_281 GBV_ILN_285 GBV_ILN_293 GBV_ILN_370 GBV_ILN_602 GBV_ILN_636 GBV_ILN_702 GBV_ILN_2001 GBV_ILN_2003 GBV_ILN_2004 GBV_ILN_2005 GBV_ILN_2006 GBV_ILN_2007 GBV_ILN_2008 GBV_ILN_2009 GBV_ILN_2010 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2015 GBV_ILN_2020 GBV_ILN_2021 GBV_ILN_2025 GBV_ILN_2026 GBV_ILN_2027 GBV_ILN_2031 GBV_ILN_2034 GBV_ILN_2037 GBV_ILN_2038 GBV_ILN_2039 GBV_ILN_2044 GBV_ILN_2048 GBV_ILN_2049 GBV_ILN_2050 GBV_ILN_2055 GBV_ILN_2057 GBV_ILN_2059 GBV_ILN_2061 GBV_ILN_2064 GBV_ILN_2065 GBV_ILN_2068 GBV_ILN_2070 GBV_ILN_2086 GBV_ILN_2088 GBV_ILN_2093 GBV_ILN_2106 GBV_ILN_2107 GBV_ILN_2108 GBV_ILN_2110 GBV_ILN_2111 GBV_ILN_2112 GBV_ILN_2113 GBV_ILN_2116 GBV_ILN_2118 GBV_ILN_2119 GBV_ILN_2122 GBV_ILN_2129 GBV_ILN_2143 GBV_ILN_2144 GBV_ILN_2147 GBV_ILN_2148 GBV_ILN_2152 GBV_ILN_2153 GBV_ILN_2188 GBV_ILN_2190 GBV_ILN_2232 GBV_ILN_2336 GBV_ILN_2446 GBV_ILN_2470 GBV_ILN_2472 GBV_ILN_2507 GBV_ILN_2522 GBV_ILN_2548 GBV_ILN_4035 GBV_ILN_4037 GBV_ILN_4046 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4242 GBV_ILN_4246 GBV_ILN_4249 GBV_ILN_4251 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4326 GBV_ILN_4333 GBV_ILN_4334 GBV_ILN_4335 GBV_ILN_4336 GBV_ILN_4338 GBV_ILN_4393 GBV_ILN_4700 |
container_issue |
1-2 |
title_short |
How athletes’ rights can be better protected when it comes to retroactive Therapeutic Use Exemptions |
url |
https://dx.doi.org/10.1007/s40318-019-00154-7 |
remote_bool |
true |
author2 |
Kaiser, Matthew |
author2Str |
Kaiser, Matthew |
ppnlink |
74670285X |
mediatype_str_mv |
c |
isOA_txt |
false |
hochschulschrift_bool |
false |
doi_str |
10.1007/s40318-019-00154-7 |
up_date |
2024-07-03T20:30:29.395Z |
_version_ |
1803591225859637248 |
fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">SPR036949566</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230328165955.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">201007s2019 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1007/s40318-019-00154-7</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)SPR036949566</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(SPR)s40318-019-00154-7-e</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Greene, Paul</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">How athletes’ rights can be better protected when it comes to retroactive Therapeutic Use Exemptions</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2019</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">© T.M.C. Asser Instituut 2019</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Abstract Therapeutic Use Exemptions (‘TUEs’) provide athletes a route to take prohibited substances for medically supported therapeutic reasons without violating anti-doping rules. They were instituted for the purpose of protecting an athlete’s right to medical care; however, the current retroactive TUE policy under the World Anti-Doping Program fails to uphold this right. In order to obtain a retroactive TUE, athletes are required to prove not only that they meet the criteria for obtaining a prospective TUE (i.e., their use of a prohibited substance or method is medically necessary and will not enhance their performance above a normal state of health) but also that their circumstances fall into one of four ‘exceptions’. The ‘fairness provision’—the last of the four exceptions—is the ‘catch-all’ provision that permits athletes to receive a retroactive TUE only if both the World Anti-Doping Agency (‘WADA’) and the relevant Anti-Doping Organization agree that fairness requires the grant of a retroactive TUE. Since its inception, this ‘fairness provision’ has been narrowly interpreted by TUE Committees, thus preventing athletes from avoiding anti-doping rule violations even in instances where they have met the test to obtain a prospective TUE. The Ultimate Fighting Championship’s (‘UFC’) TUE Policy, in contrast to WADA’s policy, more broadly permits athletes to obtain retroactive TUEs, in the end helping them avoid getting caught up in the anti-doping system. As the fourth edition of the WADA Code will be approved in the next year, we believe WADA stakeholders should consider a broader and more equitable use of the ‘fairness’ provision or adapt its policy to better protect all athletes’ right to medical care.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Therapeutic Use Exemptions</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">World Anti-Doping Code</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">International Standard for Therapeutic Use Exemptions</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Ultimate Fighting Championship</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Retroactive TUE</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Prospective TUE</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Fairness</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Kaiser, Matthew</subfield><subfield code="0">(orcid)0000-0002-2234-917X</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="t">The international sports law journal</subfield><subfield code="d">Berlin : Springer, 2002</subfield><subfield code="g">19(2019), 1-2 vom: 12. Juli, Seite 29-37</subfield><subfield code="w">(DE-627)74670285X</subfield><subfield code="w">(DE-600)2716249-7</subfield><subfield code="x">2213-5154</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:19</subfield><subfield code="g">year:2019</subfield><subfield code="g">number:1-2</subfield><subfield code="g">day:12</subfield><subfield code="g">month:07</subfield><subfield code="g">pages:29-37</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://dx.doi.org/10.1007/s40318-019-00154-7</subfield><subfield code="z">lizenzpflichtig</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_SPRINGER</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_11</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_31</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_32</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_70</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_90</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_100</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_120</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_138</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_150</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_171</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_184</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_187</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_224</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_250</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_281</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_370</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_636</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_702</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2001</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2003</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2004</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2005</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2006</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2007</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2008</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2009</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2010</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2011</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2015</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2020</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2021</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2025</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2026</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2027</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2031</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2034</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2038</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2039</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2044</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2048</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2049</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2050</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2055</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2057</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2059</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2061</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2064</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2065</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2068</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2070</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2086</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2088</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2093</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2106</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2107</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2108</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2111</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2113</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2116</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2118</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2119</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2122</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2129</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2143</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2144</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2147</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2148</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2152</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2153</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2188</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2190</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2232</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2336</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2446</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2470</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2472</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2507</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2522</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2548</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4035</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4046</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4242</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4246</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4251</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4326</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4333</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4334</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4335</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4336</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4393</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">19</subfield><subfield code="j">2019</subfield><subfield code="e">1-2</subfield><subfield code="b">12</subfield><subfield code="c">07</subfield><subfield code="h">29-37</subfield></datafield></record></collection>
|
score |
7.3981476 |